OPK as reported
OPKO Health, Inc. reported $581M of revenue over the trailing twelve months, −16% on the year before. 11 reported series are charted on this page, each one as filed.
$581M
Revenue, trailing twelve months · to Q1 2026 · −16% against the twelve months before
- Net Income
- −$213M
Net Income · +446% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$174M
Free Cash Flow · −16% year on year · trailing twelve months to Q1 2026
- Op Margin
- −18%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $581M | −16% | Q1 2026 |
| Net Income | −$213M | +446% | Q1 2026 |
| EPS | −$0.27 | +286% | Q1 2026 |
| Gross Margin | 36% | n/a | Q1 2026 |
| Op Margin | −18% | n/a | Q1 2026 |
| Net Margin | −36% | n/a | Q1 2026 |
| ROE | −16% | n/a | Q1 2026 |
| ROA | −10% | n/a | Q1 2026 |
| ROIC | −12% | n/a | Q1 2026 |
| Free Cash Flow | −$174M | −16% | Q1 2026 |
| P/E | 42.9 | n/a | Q3 2021 · 18 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
OPKO Health, Inc. (OPK) - Revenue & ProfitRevenue & ProfitOPKO Health, Inc. (OPK)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #15 of 29 by Smart Score